USFDA clears inspection at Ind Swift Lab Derabassi unit without observations

The USFDA has cleared this inspection without any 483 observations.

Mar 16, 2020 10:03 IST India Infoline News Service

Ind Swift Laboratories Limited on Friday announced the completion of inspection by the United States Food and Drug Administration (USFDA) of its API manufacturing facility at Derabassi (Punjab), near Chandigarh, India, which was conducted from March 9-13, 2020.

The USFDA has cleared this inspection without any 483 observations.

The Derabassi API manufacturing facility of the Company, which has 22 Independent manufacturing blocks, is one of the Largest Manufacturing facility of Northern India, with an annual manufacturing capacity of 695 tonnes per annum.

The facility has all the regulatory approvals including those of USFDA, TGA, PMDA, COFEPRIS, ANVISA, KFDA, EDQM, the company added.

Ind-Swift Laboratories Ltd is currently trading at Rs17.35, up by Rs0.8 or 4.83% from its previous closing of Rs16.55 on the BSE.

The scrip opened at Rs17 and has touched a high and low of Rs17.35 and Rs16.75 respectively.

Related Story